Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat
Journal of Cellular and Molecular Medicine · 2026
DOI: 10.1111/jcmm.71330 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Tian-Qi Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, People's Hospital of Yangjiang, Yangjiang, People's Republic of China. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Prostatic Neoplasms, Pyridones, Biphenyl Compounds. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Plan Project of Yangjiang.
Abstract (Originalsprache)
The enhancer of zeste homologue 2 inhibitor (EZH2i) Tazemetostat (EPZ‐6438) has demonstrated antitumour efficacy in various malignancies. This study aims to evaluate its radiosensitising potential and underlying mechanisms in prostate cancer (PCa). In vitro functional assays, including wound healing, Transwell invasion, EdU proliferation, flow cytometry, and Western blotting, were employed to assess invasion, migration, proliferation, and apoptosis. DNA damage was evaluated via comet assay, immunofluorescence staining of γH2AX/53BP1 foci, and Western blot. In vivo effects on tumour progression and survival were examined in mouse models using immunohistochemistry and TUNEL apoptosis assays. Safety was also systematically evaluated. The combination of Tazemetostat and irradiation significantly suppressed PCa cell invasion, migration, and proliferation, and promoted apoptosis compared to radiation alone. In vivo, the combination group showed inhibited tumour growth, reduced invasion, induced apoptosis, and extended survival. Mechanistically, EZH2 inhibition enhanced radiation‐induced DNA damage, increased double‐strand breaks (DSBs), and impaired DSB repair capacity. The combination therapy exhibited a favourable safety profile without observable systemic toxicity. Tazemetostat effectively enhances radiosensitivity in PCa models by augmenting DNA damage and compromising repair mechanisms. These results support the clinical translation of EZH2 inhibition as a novel radiosensitising strategy for PCa patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, People's Hospital of Yangjiang, Yangjiang, People's Republic of China.
- First School of Clinical Medicine, Health Science Center, Lanzhou University, Lanzhou, People's Republic of China.
- Department of Radiation Medicine, Biomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People's Republic of China.
- Department of Oncology, Guangyuan Central Hospital, Guangyuan, People's Republic of China.
- Department of Urology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, People's Republic of China.
- School of Mechanical and Energy Engineering, Guangdong Ocean University, Yangjiang, People's Republic of China.
ORCID-Profile: Tian-Qi Du
Förderung
- Science and Technology Plan Project of Yangjiang
Zitieren
APA
Du, T. Q., Ou, Y., Liu, R. J., Feng, Y., Li, Y., Chen, G., & Wu, X. (2026). Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71330
Vancouver
Du TQ, Ou Y, Liu RJ, Feng Y, Li Y, Chen G, et al. Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71330
BibTeX
@article{Du2026,
author = {Du, Tian-Qi and Ou, Yuhong and Liu, Rui-Ji and Feng, Yi and Li, Yaxun and Chen, Gang and Wu, Xingyu},
title = {Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
doi = {10.1111/jcmm.71330}
}
EUVIMED